Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1262-1269

  Gavegnano, Christina ^a,b   Detorio, Mervi A ^a,b   Bassit, Leda ^a,b   Hurwitz, Selwyn J ^a,b   North, Thomas W ^a   Schinazi, Raymond F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; CARBOVIR; COLONY STIMULATING FACTOR 1; LAMIVUDINE; NUCLEOSIDE ANALOG; RALTEGRAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL;

ARTICLE; CELL LEVEL; CELL TYPE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE; MACROPHAGE; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENINE; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; LYMPHOCYTES; MACROPHAGE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; ORGAN SPECIFICITY; ORGANOPHOSPHONATES; PRIMARY CELL CULTURE; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84874097081     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02012-12     Document Type: Article

References (44)

1. Gavegnano C, Fromentin E, Schinazi RF. 2009. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir. Chem. Chemother. 20:63-78.
2. Aquaro S, Balestra E, Cenci E, Francesconi M, Calio R, Perno CF. 1997. HIV infection in macrophage: role of long-lived cells and related therapeutical strategies. J. Biol. Regul. Homeost Agents 11:69 -73.
3. Balestra E, Perno CF, Aquaro S, Panti S, Bertoli A, Piacentini M, Forbici F, D'Arrigo R, Calio R, Garaci R. 2001. Macrophages: a crucial reservoir for human immunodeficiency virus in the body. J. Biol. Regul. Homeost. Agents 15:272-276.
4. Gorry PR, Churchill M, Crowe SM, Cunningham AL, Gabuzda D. 2005. Pathogenesis of macrophage tropic HIV-1. Curr. HIV Res. 3:53- 60.
5. Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11:723-737.
6. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O'Connor MJ, Doms RW, Gonzalez-Scarano F. 1999. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J. Virol. 73:205-213.
7. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
8. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, Balestra E, Calio R, Perno CF. 2002. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 68:479-488.
9. Perno CF, Aquaro S, Rosenwirth S, Balestra E, Peichl P, Billich A, Villani N, Calio R. 1994. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J. Leukoc. Biol. 56:381-386.
10. Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R, Yarchoan R. 1998. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 178:413- 422.
11. Perno CF, Yarchoan R, Balzarini J, Bergamini A, Milanese G, Pauwels R, De Clercq E, Rocchi R, Calio R. 1992. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res. 17:289 -304.
12. Chu H, Wang JJ, Qi M, Yoon JJ, Wen X, Chen X, Ding L, Spearman P. 2012. The intracellular virus-containing compartments in primary human macrophages are largely inaccessible to antibodies and small molecules. PLoS One 7:e35297. doi:10.1371/journal.pone.0035297.
13. Szebeni J, Patel SS, Hung K, Wahl LM, Weinstein JN. 1991. Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'- deoxythymidine (zidovudine) in human mononuclear cells. Antimicrob. Agents Chemother. 35:198 -200.
14. Fromentin E, Gavegnano C, Obikhod A, Schinazi RF. 2010. Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry. Anal. Chem. 82:1982-1989.
15. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B. 2004. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279:51545- 51553.
16. Weinstein JN, Bunow B, Weislow OS, Schinazi RF, Wahl SM, Wahl LM, Szebeni J. 1990. Synergistic drug combinations in AIDS therapy. Dipyridamole/3'-azido- 3'-deoxythymidine in particular and principles of analysis in general. Ann. N. Y. Acad. Sci. 616:367-384.
17. Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Ellis R, Capparelli EV, Grant I. 2009. Low atazanavir concentrations in cerebrospinal fluid. AIDS 23:83- 87.
18. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AD, Gelman BB, Mbeo G, McCutchan JA, Simpson DM, Haubrich R, Ellis R, Grant I. 2011. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J. Antimicrob. Chemother. 66:354 -357.
19. Tashima KT, Caliendo AM, Ahmad M, Gormley JM, Fiske WD, Brennan JM, Flanigan TP. 1999. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J. Infect. Dis. 180:862- 864.
20. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, Collier A, Gelman B, Marra C, Mbeo G, McCutchan A, Morgello S, Simpson D, Way L, Vaida F, Ueland S, Capparelli E, Grant I. 2010. Total raltegravir concentrations in cerebrospinal fluid exceed the 50- percent inhibitory concentration for wild-type HIV-1. Antimicrob. Agents Chemother. 54:5156 -5160.
21. Best BM, Letendre SL, Koopmans P, Rossi SS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Capparelli EV, Ellis RJ, Grant I. 2012. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J. Acquir. Immune Defic. Syndr. 59:376 -381.
22. Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, Li C, Morgello S, Gabuzda D. 2012. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 7:e30881. doi:10.1371/journal.pone.0030881.
23. Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, Kramski M, Hearps AC, Cameron PU, Lewin SR, Crowe SM, Jaworowski A. 2012. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J. Immunol. 189:1491-1499.
24. Reus S, Portilla J, Sanchez-Paya J, Giner L, Frances R, Such J, Boix V, Merino E, Gimeno A. 2012. Low-level HIV viraemia is associated with microbial translocation and inflammation. J. Acquir. Immune Defic. Syndr. [Epub ahead of print.] doi:10.1097/QAI.0b013e3182745ab0.
25. Moss D, Kwan WS, Liptrott N, Siccardi M, Anstee D, Khoo S, Back D, Owen A. 2010. Raltegravir is a substrate for the influx transporters OAT1 and PEPT1 and the efflux transporter Pgp but is not transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2, abstr. 613. 17th Conf. Retrovir. Opportunistic Infect.: Progr. Abstr., February 16-19, 2010, Moscone Center West, San Francisco, CA, U. S. A.
26. Ambudkar SV, Kim IW, Sauna ZE. 2006. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur. J. Pharm. Sci. 27:392- 400.
27. Callaghan R, Ford RC, Kerr ID. 2006. The translocation mechanism of P-glycoprotein. FEBS Lett. 580:1056 -1063.
28. Scopelliti F, Pollicita M, Ceccherini-Silberstein F, Di Santo F, Surdo M, Aquaro S, Perno CF. 2011. Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Res. 92:255-261.
29. Gavegnano C, Kennedy EM, Kim B, Schinazi RF. 2012. The impact of macrophage nucleotide pools on HIV-1 reverse transcription, viral replication, and the development of novel antiviral agents. Mol. Biol. Int. 2012: 625983. doi:10.1155/2012/625983.
30. Kennedy EM, Gavegnano C, Nguyen L, Slater R, Lucas A, Fromentin F, Schinazi RF, Kim B. 2010. Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J. Biol. Chem. 285:39380 -39391.
31. Becker Y. 2004. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers-a review and hypothesis. Virus Genes 28:5-18.
32. Kedzierska K, Crowe SM, Turville S, Cunningham AL. 2003. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev. Med. Virol. 13:39 -56.
33. Jacobsson B, Britton S, He Q, Karlsson A, Eriksson S. 1995. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retroviruses 11:805- 811.
34. Jacobsson B, Britton S, Tornevik Y, Eriksson S. 1998. Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. Biochem. Pharmacol. 56:389 -395.
35. Wurtzer S, Compain S, Benech H, Hance AJ, Clavel F. 2005. Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1. J. Virol. 79:14815-14821.
36. Viora M, Di Genova G, Rivabene R, Malorni W, Fattorossi A. 1997. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs. Int. J. Immunopharmacol. 19:311-321.
37. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41: 1099-1107.
38. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, Averett DR, Krenitsky TA. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
39. Schinazi RF, Hernandez-Santiago BI, Hurwitz SJ. 2006. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res. 71:322-334.
40. Sharma PL, Nurpeisov V, Hernandez-Santiago BI, Beltran T, Schinazi RF. 2004. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr. Top. Med. Chem. 4:895-919.
41. Anderson P, Meditz A, Zheng JH, Predhomme J, Klein B, Guida L, McCallister K, Fernandez C, Kiser J, Bushman L. 2012. Cellular pharmacology of tenofovir and emtricitabine in blood, rectal, and cervical cells from HIV- volunteers, abstr. 587. 19th Annual Conference on Retroviruses and Opportunistic Infections, Seattle, WA, U. S. A.
42. Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF. 2010. Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV- 1-infected individuals. Antivir. Ther. 15:185-192.
43. Hurwitz SJ, Asif G, Fromentin E, Tharnish PM, Schinazi RF. 2010. Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals. Antimicrob. Agents Chemother. 54:1248 -1255.
44. Hernandez-Santiago BI, Obikhod A, Fromentin E, Hurwitz SJ, Schinazi RF. 2007. Short communication cellular pharmacology of 9-(beta-D-1, 3- dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes. Antivir. Chem. Chemother. 18:343-346.